The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Claudin 18.2 Targeted Therapy Market Over The 2026–2030 Period?
The claudin 18.2 targeted therapy market size has demonstrated substantial growth in recent years. It is projected to increase from $1.6 billion in 2025 to $1.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. The expansion observed historically is attributable to factors such as the rising prevalence of gastric and gastrointestinal cancers, advancements in antibody engineering technologies, the broadening scope of oncology-focused clinical trials, increased investments in targeted cancer therapies, and a deeper understanding of claudin protein biology.
The claudin 18.2 targeted therapy market is anticipated to experience significant expansion over the coming years. This market is projected to reach $4.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. This anticipated growth during the forecast period stems from factors such as a rise in regulatory clearances for targeted oncology medications, a heightened need for individualized cancer care, the broadening of combination therapy strategies, increasing investments in oncology pipelines, and a greater uptake of precision diagnostic tools. Key trends observed within the forecast timeframe encompass an intensified emphasis on biomarker-guided oncology treatments, an increase in the creation of claudin 18.2 monoclonal antibodies, the expanding scope of targeted therapies specific to certain indications, improved incorporation of companion diagnostics, and a surge in strategic partnerships within the field of precision oncology.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp
What Underlying Factors Are Accelerating The Growth Of The Claudin 18.2 Targeted Therapy Market?
The increasing occurrence of gastrointestinal cancers is projected to fuel the expansion of the claudin 18.2 targeted therapy market moving forward. Gastrointestinal (GI) cancers are defined as malignant growths emerging anywhere along the digestive system, from the esophagus down to the rectum. The surge in these cancers is largely attributed to unhealthy diets, particularly those high in processed items and deficient in fiber, which contributes to gut inflammation and heightened cancer susceptibility. Claudin 18.2 targeted therapy offers a treatment approach for gastrointestinal cancers by specifically targeting the Claudin 18.2 protein, which is found in excessive amounts on cancer cells. This mechanism allows drugs or antibodies to eradicate cancerous cells while preserving healthy tissue, thereby enhancing the efficacy of the treatment. For example, in June 2025, the Centers for Disease Control and Prevention (CDC), a US public health agency, reported 147,931 new colorectal cancer cases in 2022, with 53,779 deaths from colorectal cancer recorded in 2023. Consequently, the rising prevalence of gastrointestinal cancers is propelling the growth of the Claudin 18.2 targeted therapy market.
How Is The Claudin 18.2 Targeted Therapy Market Segmented Across Key Categories?
The claudin 18.2 targeted therapy market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors
Which Upcoming Trends Are Expected To Influence The Claudin 18.2 Targeted Therapy Market?
Major companies within the claudin 18.2 targeted therapy market are concentrating on developing innovative solutions, such as monoclonal antibodies, with the goal of specifically targeting cancer cells that express claudin 18.2 and improving treatment outcomes. A monoclonal antibody is a protein engineered in a laboratory, designed to bind precisely to a single target, like a protein on the surface of cancer cells, which helps the immune system recognize and attack these cells. For instance, in March 2024, Astellas Pharma Inc., a pharmaceutical company based in Japan, secured approval from Japan’s Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively attaches to the CLDN18.2 protein on tumor cells, prompting the immune system to destroy them. Clinical trials showed it notably enhances progression-free and overall survival when administered with chemotherapy compared to chemotherapy alone. This innovative therapy provides a novel, effective option for patients with HER2-negative, CLDN18.2-positive tumors, addressing an unmet need in aggressive gastric cancer.
Who Are The Dominant Players Shaping The Claudin 18.2 Targeted Therapy Market Landscape?
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
Read the full claudin 18.2 targeted therapy market report here:
https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report
Which Region Is Projected To Dominate The Claudin 18.2 Targeted Therapy Market During The Forecast Period?
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Claudin 18.2 Targeted Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28169&type=smp
Browse Through More Reports Similar to the Global Claudin 18.2 Targeted Therapy Market 2026, By The Business Research Company
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Coronavirus Current Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
Next Generation Antibody Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model